Ezetimibe

依折麦布

Report date: 2022/08/16 20:00:19
NMEFirst In Class

Base Information

Drug NameEzetimibe
Drug Alias Name依折替米贝AbsorcolEzedoc依泽麦布依替米贝 +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNiemann-Pick C1-like protein 1 inhibitorsCholesterol absorption inhibitors
TargetsNiemann-Pick C1-like protein 1
Therapy Area/IndicationsSitosterolemiaHomozygous familial hypercholesterolemiaHypertriglyceridemia +[22] 
Global Approved IndicationsSitosterolemiaHomozygous familial hypercholesterolemiaHypercholesterolemia +[6] 
Approved Indications in ChinaHypercholesterolemia
Original Approved Country/TerritoryUnited States
Original Approved Date2002/10/25
Country/TerritoryCanadaUnited StatesPakistan +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSchering-Plough Labo Nv
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme CorpMsd Pharma (Singapore) Pte LtdOrganon LLC
Inactive CompaniesJw Pharmaceutical CorpGlaxosmithkline PlcWashington University School Of Medicine +[16] 
Active IndicationsSitosterolemiaHomozygous familial hypercholesterolemiaHypercholesterolemia +[7] 
Inactive IndicationsHypertriglyceridemiaMetabolic SyndromeDiabetes Mellitus, Type 2 +[15] 

Other Information

ATC CodeC10AX09
Related LinksWikipediaDrugBankKEGG